BACKGROUND: Although inflammation and apoptosis are known to play important roles in cisplatin nephrotoxicity, the exact intracellular signaling mechanisms are not well understood. Recent reports that extracellular signal-regulated kinase (ERK1/2) pathway mediates cisplatin-induced caspase activation and apoptosis in cultured renal tubular cells led us to investigate the effect of MAPK/ERK kinase (MEK) inhibitor, an immediate upstream of ERK1/2 in cisplatin-induced acute renal failure (ARF) in mice. METHODS: The effect of MEK/ERK1/2 inhibition on kidney tumor necrosis factor-alpha (TNF-alpha (gene expression, inflammation, the activation of tissue caspases, and apoptosis were examined in addition to its effects on renal function and histology in cisplatin-induced ARF in mice. RESULTS: Pretreatment of MEK inhibitor, U0126, decreased ERK1/2 phosphorylation following cisplatin administration with significant functional and histologic protection. This beneficial effect was accompanied by decrease in TNF-alpha gene expression level and inflammation, as well as in caspase 3 activity and apoptosis. CONCLUSION: These data provide evidence that ERK1/2 pathway functions as an upstream signal for TNF-alpha-mediated inflammation and caspase 3-mediated apoptosis in cisplatin-induced ARF in mice and suggest that ERK1/2 can be a novel therapeutic target in cisplatin nephrotoxicity.
BACKGROUND: Although inflammation and apoptosis are known to play important roles in cisplatinnephrotoxicity, the exact intracellular signaling mechanisms are not well understood. Recent reports that extracellular signal-regulated kinase (ERK1/2) pathway mediates cisplatin-induced caspase activation and apoptosis in cultured renal tubular cells led us to investigate the effect of MAPK/ERK kinase (MEK) inhibitor, an immediate upstream of ERK1/2 in cisplatin-induced acute renal failure (ARF) in mice. METHODS: The effect of MEK/ERK1/2 inhibition on kidney tumor necrosis factor-alpha (TNF-alpha (gene expression, inflammation, the activation of tissue caspases, and apoptosis were examined in addition to its effects on renal function and histology in cisplatin-induced ARF in mice. RESULTS: Pretreatment of MEK inhibitor, U0126, decreased ERK1/2 phosphorylation following cisplatin administration with significant functional and histologic protection. This beneficial effect was accompanied by decrease in TNF-alpha gene expression level and inflammation, as well as in caspase 3 activity and apoptosis. CONCLUSION: These data provide evidence that ERK1/2 pathway functions as an upstream signal for TNF-alpha-mediated inflammation and caspase 3-mediated apoptosis in cisplatin-induced ARF in mice and suggest that ERK1/2 can be a novel therapeutic target in cisplatinnephrotoxicity.
Authors: Jered V McGivern; Teresa N Patitucci; Joshua A Nord; Marie-Elizabeth A Barabas; Cheryl L Stucky; Allison D Ebert Journal: Glia Date: 2013-07-10 Impact factor: 7.452
Authors: Min Tao; Yingfeng Shi; Lunxian Tang; Yi Wang; Lu Fang; Wei Jiang; Tao Lin; Andong Qiu; Shougang Zhuang; Na Liu Journal: Am J Physiol Renal Physiol Date: 2019-01-16
Authors: Alan R Parrish; Gang Chen; Robert C Burghardt; Takaho Watanabe; Christophe Morisseau; Bruce D Hammock Journal: Cell Biol Toxicol Date: 2008-04-03 Impact factor: 6.691
Authors: Myung-Gyu Kim; Ha Na Yang; Hye-Won Kim; Sang-Kyung Jo; Won Yong Cho; Hyoung-Kyu Kim Journal: J Korean Med Sci Date: 2010-03-19 Impact factor: 2.153
Authors: Jingfei Cheng; Wei Zhou; Gina M Warner; Bruce E Knudsen; Vesna D Garovic; Catherine E Gray; Lilach O Lerman; Jeffrey L Platt; J Carlos Romero; Stephen C Textor; Karl A Nath; Joseph P Grande Journal: Am J Physiol Renal Physiol Date: 2009-07-22